drugset
drugset / Trial / NCT05322954

Study of the Safety and Feasibility of Psilocybin in Adults With Methamphetamine Use Disorder

NCT05322954 ↗

Phase 1 Terminated 5 enrolled University of Wisconsin, Madison Revive Therapeutics, Ltd. · collab
NaSingle-groupOpen-labelHealth-services research

Summary

The purpose of this research study is to investigate the safety and feasibility of two (2) oral doses of psilocybin when combined with behavioral support for methamphetamine use disorder (MUD). Participants have a diagnosis of methamphetamine use disorder (MUD). Participants can expect to be actively engaged in the study for up to 26 weeks.

Timeline

Start
2023-03-03
Primary completion
2024-03-07
Completion
2024-03-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Psilocybin Other / unclassified 25 mg Oral
Subject Psilocybin Other / unclassified 50 mg Oral

Indications

methamphetamine dependence